Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6 S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5 H-imidazo[2,1-b][1,3]oxazine (PA-824)

Journal of Medicinal Chemistry

Volumn 53, Issue 23, 2010, Pages 8421-8439

  Kmentova, Iveta ^a   Sutherland, Hamish S ^a   Palmer, Brian D ^a   Blaser, Adrian ^a   Franzblau, Scott G ^b   Wan, Baojie ^b   Wang, Yuehong ^b   Ma, Zhenkun ^c   Denny, William A ^a   Thompson, Andrew M ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 NITRO 6 [[2 [4 (TRIFLUOROMETHOXY)PHENYL] 5 PYRIMIDINYL] METHOXY] 6,7 DIHYDRO 5H IMIDAZO[2,1 B] [1,3]OXAZINE; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HYDROPHILICITY; IN VIVO STUDY; LIPOPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PH; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED BALB C; NITROIMIDAZOLES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS;

EID: 78649882763     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101288t     Document Type: Article

References (55)

1. Haydel, S. H. Extensively drug-resistant tuberculosis: a sign of the times and an impetus for antimicrobial discovery Pharmaceuticals 2010, 3, 2268-2290
2. World Health Organization. Global tuberculosis control: a short update to the 2009 report. WHO Press: Geneva, Switzerland, 2009.
3. Ma, Z.; Lienhardt, C.; McIlleron, H.; Nunn, A. J.; Wang, X. Global tuberculosis drug development pipeline: the need and the reality Lancet 2010, 375, 2100-2109
4. Burman, W. J. Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century Clin. Infect. Dis. 2010, 50, S165-S172
5. Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis Nature 2000, 405, 962-966
6. Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. OPC-67683, a nitro-dihydro- imidazooxazole derivative with promising action against tuberculosis in vitro and in mice PLoS Med. 2006, 3, 2131-2143
7. Anderson, R. F.; Shinde, S. S.; Maroz, A.; Boyd, M.; Palmer, B. D.; Denny, W. A. Intermediates in the reduction of the antituberculosis drug PA-824, (6 S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazine, in aqueous solution Org. Biomol. Chem. 2008, 6, 1973-1980
8. Singh, R.; Manjunatha, U.; Boshoff, H. I. M.; Ha, Y. H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E. PA-824 kills nonreplicating Mycobacterium tuberculosi s by intracellular NO release Science 2008, 322, 1392-1395
9. Diacon, A. H.; Pym, A.; Grobusch, M.; Patientia, R.; Rustomjee, R.; Page-Shipp, L.; Pistorius, C.; Krause, R.; Bogoshi, M.; Churchyard, G.; Venter, A.; Allen, J.; Palomino, J. C.; De Marez, T.; van Heeswijk, R. P. G.; Lounis, N.; Meyvisch, P.; Verbeeck, J.; Parys, W.; de Beule, K.; Andries, K.; McNeeley, D. F. The diarylquinoline TMC207 for multidrug-resistant tuberculosis N. Engl. J. Med. 2009, 360, 2397-2405
10. Palmer, B. D.; Thompson, A. M.; Sutherland, H. S.; Blaser, A.; Kmentova, I.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Denny, W. A. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6 S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazine (PA-824) J. Med. Chem. 2010, 53, 282-294
11. Barry, C. E.; Crick, D. C.; McNeil, M. R. Targeting the formation of the cell wall core of M. tuberculosis Infect. Disord.-Drug Targets 2007, 7, 182-202
12. Sutherland, H. S.; Blaser, A.; Kmentova, I.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Palmer, B. D.; Denny, W. A.; Thompson, A. M. Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains J. Med. Chem. 2010, 53, 855-866
13. Rivers, E. C.; Mancera, R. L. New anti-tuberculosis drugs with novel mechanisms of action Curr. Med. Chem. 2008, 15, 1956-1967
14. Hu, Y.; Coates, A. R. M.; Mitchison, D. A. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis Int. J. Tuberc. Lung Dis. 2008, 12, 69-73
15. Mitchison, D. A.; Davies, G. R. Assessment of the efficacy of new anti-tuberculosis drugs Open Infect. Dis. J. 2008, 2, 59-76
16. Garcia-Contreras, L.; Sung, J. C.; Muttil, P.; Padilla, D.; Telko, M.; VerBerkmoes, J. L.; Elbert, K. J.; Hickey, A. J.; Edwards, D. A. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs Antimicrob. Agents Chemother. 2010, 54, 1436-1442
17. Kim, P.; Kang, S.; Boshoff, H. I.; Jiricek, J.; Collins, M.; Singh, R.; Manjunatha, U. H.; Niyomrattanakit, P.; Zhang, L.; Goodwin, M.; Dick, T.; Keller, T. H.; Dowd, C. S.; Barry, C. E. Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships J. Med. Chem. 2009, 52, 1329-1344
18. Noble, S. A.; Oshiro, G.; Malecha, J. W.; Zhao, C.; Robinson, C. K. M.; Duron, S. G.; Sertic, M.; Lindstrom, A.; Shiau, A.; Bayne, C.; Kahraman, M.; Lou, B.; Govek, S. Sulfonyl-substituted bicyclic compounds as modulators of PPAR, and their preparation, pharmaceutical compositions and use for treatment of various diseases. Patent WO 2006055187 A1, 2006.
19. van Poucke, R.; Pollet, R.; de Cat, A. Preparation of aryl difluoromethyl ether, thioether and sulphone derivatives. Electronic properties of the difluoromethoxy, -methylthio, and -methylsulphonyl substituents Tetrahedron Lett. 1965, 6, 403-406
20. Biagetti, M.; Contini, S. A.; Genski, T.; Guery, S.; Leslie, C. P.; Mazzali, A.; Pizzi, D. A.; Sabbatini, F. M.; Seri, C. Spiro compounds as NPYY5 receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of eating disorders. Patent WO 2009095377 A1, 2009.
21. Ando, M.; Wada, T.; Sato, N. Facile one-pot synthesis of N -difluoromethyl-2-pyridone derivatives Org. Lett. 2006, 8, 3805-3808
22. O'Shea, P. D.; Chen, C.-Y.; Chen, W.; Dagneau, P.; Frey, L. F.; Grabowski, E. J. J.; Marcantonio, K. M.; Reamer, R. A.; Tan, L.; Tillyer, R. D.; Roy, A.; Wang, X.; Zhao, D. Practical asymmetric synthesis of a potent PDE4 inhibitor via stereoselective enolate alkylation of a chiral aryl-heteroaryl secondary tosylate J. Org. Chem. 2005, 70, 3021-3030
23. Baker, W. R.; Shaopei, C.; Keeler, E. L. Nitroimidazole antibacterial compounds and methods of use thereof. U.S. Patent 5,668,127, 1997.
24. Imperiali, B.; Prins, T. J.; Fisher, S. L. Chemoenzymatic synthesis of 2-amino-3-(2,2′-bipyridinyl)propanoic acids J. Org. Chem. 1993, 58, 1613-1616
25. Chuang, C.-L.; dos Santos, O.; Xu, X; Canary, J. W. Synthesis and cyclic voltammetry studies of copper complexes of bromo- and alkoxyphenyl-substituted derivatives of tris(2-pyridylmethyl)amine: influence of cation-alkoxy interactions on copper redox potentials Inorg. Chem. 1997, 36, 1967-1972
26. van Hemel, J.; Esmans, E. L.; Alderweireldt, F. C.; Dommisse, R. A.; de Groot, A. Synthesis and biological evaluation of some acyclic pyridine C-nucleosides. Part one Nucleosides Nucleotides 1994, 13, 2345-2366
27. Jones, G.; Pitman, M. A.; Lunt, E.; Lythgoe, D. J.; Abarca, B.; Ballesteros, R.; Elmasnaouy, M. Triazolopyridines. 18. Nucleophilic substitution reactions on triazolopyridines; a new route to 2,2′-bipyridines Tetrahedron 1997, 53, 8257-8268
28. Klunder, J. M.; Hoermann, M.; Cywin, C. L.; David, E.; Brickwood, J. R.; Schwartz, R.; Barringer, K. J.; Pauletti, D.; Shih, C.-K.; Erickson, D. A.; Sorge, C. L.; Joseph, D. P.; Hattox, S. E.; Adams, J.; Grob, P. M. Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8- Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes J. Med. Chem. 1998, 41, 2960-2971
29. van den Heuvel, M.; van den Berg, T. A.; Kellogg, R. M.; Choma, C. T.; Feringa, B. L. Synthesis of a non-heme template for attaching four peptides: an approach to artificial iron(II)-containing peroxidases J. Org. Chem. 2004, 69, 250-262
30. Sullivan, P. T.; Norton, S. J. α-Bromo- and α- chloropyridylalanines J. Med. Chem. 1971, 14, 557-558
31. Jagusch, C.; Negri, M.; Hille, U. E.; Hu, Q.; Bartels, M.; Jahn-Hoffmann, K.; Pinto-Bazurco Mendieta, M. A. E.; Rodenwaldt, B.; Muller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Recanatini, M.; Cavalli, A.; Hartmann, R. W. Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure Bioorg. Med. Chem. 2008, 16, 1992-2010
32. Schubert, U. S.; Eschbaumer, C.; Weidl, C. H. Synthesis of 5,5″- bis functionalized 2,2′:6′,2″-terpyridines using functionalized pyridine building blocks Synlett 1999, 342-344
33. Wilde, R. G.; Bakthavatchalam, R.; Beck, J. P.; Arvanitis, A. Synthesis and use of imidazopyrimidines and imidazopyridines as corticotropin releasing factor (CRF) antagonists. Patent WO 2001044248 A1, 2001.
34. Apodaca, R.; Breitenbucher, J. G.; Chambers, A. L.; Deng, X.; Hawryluk, N. A.; Keith, J. M.; Mani, N. S.; Merit, J. E.; Pierce, J. M.; Seierstad, M.; Xiao, W. Preparation of aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase. Patent WO 2009105220 A1, 2009.
35. Hegde, V. B.; Bis, S. J.; Yap, M. C. H.; Perreault, D. M.; Tisdell, F. G.; Dintenfass, L. P.; Dripps, J. E.; Gifford, J. M.; Guenthenspberger, K. A.; Karr, L. L.; Schoonover, J. R. Preparation of insecticidal 3-(2,6-disubstituted phenyl)-5-[4-(or 5-)arylthien-2-(or 3)yl]-1,2,4-triazoles. Patent WO 2003024961 A1, 2003.
36. Parmee, E. R.; Xiong, Y.; Guo, J.; Liang, R.; Brockunier, L. Pyrazole derivatives as antidiabetic agents, their preparation, pharmaceutical compositions and use in therapy. Patent US 2005272794 A1, 2005.
37. Pelcman, B.; Olofsson, K.; Katkevics, M.; Ozola, V.; Suna, E.; Kalvins, I.; Trapencieris, P. Indoles as mPGES-1 inhibitors, and their preparation, pharmaceutical compositions and their use in treatment of inflammation. Patent WO 2006077364 A1, 2006.
38. Li, W.; Nelson, D. P.; Jensen, M. S.; Hoerrner, R. S.; Cai, D.; Larsen, R. D.; Reider, P. J. An improved protocol for the preparation of 3-pyridyl- and some arylboronic acids J. Org. Chem. 2002, 67, 5394-5397
39. Senda, T.; Ogasawara, M.; Hayashi, T. Rhodium-catalysed asymmetric 1,4-addition of organoboron reagents to 5,6-dihydro-2(1 H)-pyridinones. Asymmetric synthesis of 4-aryl-2-piperidinones J. Org. Chem. 2001, 66, 6852-6856
40. Deng, J. Z.; Paone, D. V.; Ginnetti, A. T.; Kurihara, H.; Dreher, S. D.; Weissman, S. A.; Stauffer, S. R.; Burgey, C. S. Copper-facilitated Suzuki reactions: application to 2-heterocyclic boronates Org. Lett. 2009, 11, 345-347
41. Ohshita, J. Preparation of azinylmethylmalononitriles as pesticides. Patent EP 1555259 A1, 2005.
42. Kuduk, S. D.; Di Marco, C. N.; Shipe, W. D. Preparation of oxodihydroquinoline derivatives for use as M1 receptor positive allosteric modulators. Patent WO 2009134668 A2, 2009.
43. Besidski, Y.; Kers, I.; Nyloef, M.; Sandberg, L.; Skogholm, K. Preparation of heteroarylchromenylbenzamide derivatives and analogs as voltage-gated sodium channel modulators. Patent WO 2008130320 A2, 2008.
44. Kiener, A.; Roduit, J.-P.; Tschech, A.; Tinschert, A.; Heinzmann, K. Regiospecific enzymatic hydroxylations of pyrazinecarboxylic acid and a practical synthesis of 5-chloropyrazine-2-carboxylic acid Synlett 1994, 814-816
45. Arukwe, J.; Undheim, K. Organomanganese(II) reagents in the synthesis of 5-pyrimidinyl ketones Acta Chem. Scand., Ser. B 1986, B40, 764-767
46. Zhichkin, P.; Fairfax, D. J.; Eisenbeis, S. A. A general procedure for the synthesis of 2-substituted pyrimidine-5-carboxylic esters Synthesis 2002, 720-722
47. 6 J. Chem. Soc. C 1968, 1203-1208
48. Liebeskind, L. S.; Srogl, J. Heteroaromatic thioether-boronic acid cross-coupling under neutral reaction conditions Org. Lett. 2002, 4, 979-981
49. Fiandor Roman, J. M.; Bueno Calderon, J. M.; Mallo Rubio, A. Preparation of novel heterocyclic compounds, particularly 4-pyridones, as antimalarial agents. Patent WO 2006094799 A2, 2006.
50. Rho, T.; Abuh, Y. F. One-pot synthesis of pyrimidine-5-carboxaldehyde and ethyl pyrimidine-5-carboxylate by utilizing pyrimidin-5-yl-lithium Synth. Commun. 1994, 24, 253-256
51. Collins, L. A.; Franzblau, S. G. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium Antimicrob. Agents Chemother. 1997, 41, 1004-1009
52. Cho, S. H.; Warit, S.; Wan, B.; Hwang, C. H.; Pauli, G. F.; Franzblau, S. G. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2007, 51, 1380-1385
53. Falzari, K.; Zhu, Z.; Pan, D.; Liu, H.; Hongmanee, P.; Franzblau, S. G. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2005, 49, 1447-1454
54. Hickey, D. M. B.; Ife, R. J.; Leach, C. A.; Smith, S. A. Preparation of 1-(piperazinylcarbonylalkyl)-2-(arylalkylthio)-4-pyrimidinones as lipoprotein associated phospholipase A2 inhibitors. Patent WO 2000066566 A1, 2000.
55. Ewing, W. R.; Becker, M. R.; Choi-Sledeski, Y. M.; Pauls, H. W.; He, W.; Condon, S. M.; Davis, R. S.; Hanney, B. A.; Spada, A. P.; Burns, C. J.; Jiang, J. Z.; Li, A.; Myers, M. R.; Lau, W. F.; Poli, G. B. Substituted piperazinone derivatives and other oxoazaheterocyclyl compounds useful as factor Xa/IIa inhibitors. Patent WO 2001007436 A2, 2001.